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The surgical management of breast cancer has evolved over
theyearsfromextensiveradicalmastectomytobreastconser-
vation surgery. Until the introduction of the sentinel lymph
node biopsy (SLNB), all patients with invasive breast cancer
would undergo complete axillary lymph node dissection
( A L N D )a n dt h u sb ea tr i s ko fs u ﬀering from its associated
high morbidity. SLNB has become the standard of care and
represented signiﬁcant progress toward reducing the invasive
proceduresforthemanagementoftheaxilla.Themostrecent
clinical trials (NSABP-B32 and ACOSOG Z0011) performed
in patients that underwent SLNB support this procedure as
an accurate predictor of the risk of further axillary node
involvement and of breast cancer recurrence. Additionally,
the ACOSOG Z0011 trial challenged the standard of practice
inthemanagementoftheaxilla,inwhichALNDismandated
for all the patients with a positive sentinel node. A similar
outcome was demonstrated for a selected group of patients
(treated with breast conserving surgery and radiotherapy)
with positive SLNB then followed by ALND or SLNB only.
In light of these results, the role of ALND in the current
managementofbreastcancerisbeing reevaluatedforspeciﬁc
patient subpopulations. In this special issue, this timely
subjectisprovocativelyreviewedinadditiontootherrelevant
topics, such as the controversial meaning of the presence
of micrometastasis and isolated tumor cells in the SLN in
r e l a t i o nt ol o c a lr e c u r r e n c ea n do v e r a l ls u r v i v a la n dt h e
feasibility of performing SLNB after neoadjuvant treatment
and transaxillary breast augmentation.
Despite the advances in the lymphatic mapping and in
the intraoperative methods for SLN analysis, the accurate
identiﬁcation of tumor cells in this node continues to be a
challenge in clinical practice, and signiﬁcant false-negative
results in SLNB are still observed. In a research study
published in this issue, a preferential cellular distribution of
themalignantcellsintheSLNisreported,suggestingthatthe
pathological analysis directed to this area may contribute to
a more precise identiﬁcation of nodal metastasis. Additional
progressinthisdirectioninvolves thedevelopment ofmolec-
ular markers, which would tackle not only the misdiagnosed
SLN-negative patients but also the ones with low risk of
recurrence that are unnecessarily submitted to SLNB. In this
sense, the Bayesian-based nomogram developed by Westover
et al. is proposed to be particularly useful, especially in cases
where the SLNB assessment is predicted to be less sensitive.
Thisnomogramwouldalsoleadtotheidentiﬁcationofhigh-
risk individuals for recurrence, based on the calculation of
residual axillary disease risk, despite a negative SLNB.
Several new reports, mostly based on gene expression
proﬁling,havesuggestedthatthediﬀerentratesofrecurrence
can be due to the distinct molecular types of breast cancer.
The development of a genomic signature that eﬀectively
discriminates patients by lymph node status, as the one
proposed by Ellsworth et al., could stratify patients based on
their need of surgical evaluation of the lymph nodes, sparing
the ones in which disease will probably be limited to its
primarysite.Theassessmentofspeciﬁctumormarkersinthe2 International Journal of Breast Cancer
lymph nodes is also discussed in this special issue, including
a review of the prognostic and/or predictive implications
of lymph node metastasis in tumors with elevated levels
of CXCR4 (a protein chemokine receptor) and VEGF-C (a
vascular endothelial cellular growth factor).
From the Halsted radical mastectomy to the commercial
gene expression proﬁling tests, axillary lymph node manage-
ment and recurrence prediction are still evolving topics for
patients with breast cancer. The continued improvement of
molecular tumor proﬁling and bioinformatics from larger
and better deﬁned patient cohorts will certainly provide
answers to many challenging questions regarding the axillary
metastatic process. The clariﬁcation of this complex molecu-
larmechanismandtheidentiﬁcationofnovelandintegrative
molecular markers that can reliably predict lymph node
involvement that will aﬀect risk of recurrence and survival
willcontinuetoformthebasisofthecontemporaryapproach
for breast cancer management, where an early prediction of
axillary metastasis and a personalized cancer treatment can
be achieved.
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